logo

Tg Therapeutics Inc. (TGTX)



Trade TGTX now with
  Date
  Headline
8/25/2022 7:43:06 AM TG Therapeutics Publishes Results From ULTIMATE I & II Phase 3 Trials In The New England Journal Of Medicine
6/3/2022 7:53:16 AM TG Presents Exploratory Analyses From ULTIMATE I & II Phase 3 Trials Of Ublituximab In Multiple Sclerosis
5/31/2022 7:42:11 AM TG Therapeutics:FDA Extends PDUFA Goal Date For Ublituximab BLA To Treat Patients With RMS To Dec 28
4/6/2022 7:50:23 AM TG Therapeutics Presents Data From ULTIMATE I & II Phase 3 Trials Of Ublituximab In Multiple Sclerosis At AAN Meeting
12/14/2021 7:29:08 AM TG Therapeutics Announces FDA Acceptance Of BLA For Ublituximab As A Treatment ForRelapsing Forms Of Multiple Sclerosis
9/30/2021 7:35:22 AM TG Therapeutics Submits BLA For Ublituximab For Relapsing Forms Of Multiple Sclerosis
6/18/2021 7:40:58 AM TG Therapeutics Announces Data From Two Presentations Evaluating TG-1701
5/25/2021 7:11:16 AM TG Therapeutics Says FDA Accepted BLA For Ublituximab In Combination With UKONIQ
5/10/2021 8:05:09 AM TG Therapeutics Q1 Net Loss $90.6 Mln
9/26/2018 8:48:41 AM Jefferies Is Cutting TG Therapeutics Inc. (TGTX) FY20 Estimate To -2.35 From -1.69
9/26/2018 8:48:25 AM Jefferies Is Lowering TG Therapeutics Inc. (TGTX) FY19 Estimate To -1.98 From -1.88